Amyloid oligomers: A joint experimental/computational perspective on Alzheimer's disease, Parkinson's disease, type II diabetes, and amyotrophic lateral sclerosis

PH Nguyen, A Ramamoorthy, BR Sahoo… - Chemical …, 2021 - ACS Publications
Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

Impaired dopamine metabolism in Parkinson's disease pathogenesis

A Masato, N Plotegher, D Boassa… - Molecular …, 2019 - Springer
A full understanding of Parkinson's Disease etiopathogenesis and of the causes of the
preferential vulnerability of nigrostriatal dopaminergic neurons is still an unsolved puzzle. A …

The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability

E Hallacli, C Kayatekin, S Nazeen, XH Wang… - Cell, 2022 - cell.com
Alpha-synuclein (αS) is a conformationally plastic protein that reversibly binds to cellular
membranes. It aggregates and is genetically linked to Parkinson's disease (PD). Here, we …

Alpha-synuclein aggregation in Parkinson's disease

E Srinivasan, G Chandrasekhar… - Frontiers in …, 2021 - frontiersin.org
Parkinson's disease (PD), a neurodegenerative disorder characterized by distinct aging-
independent loss of dopaminergic neurons in substantia nigra pars compacta (SNpc) region …

The docking of synaptic vesicles on the presynaptic membrane induced by α-synuclein is modulated by lipid composition

WK Man, B Tahirbegi, MD Vrettas, S Preet… - Nature …, 2021 - nature.com
Abstract α-Synuclein (αS) is a presynaptic disordered protein whose aberrant aggregation is
associated with Parkinson's disease. The functional role of αS is still debated, although it …

DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson's disease

A Masato, N Plotegher, F Terrin, M Sandre… - npj Parkinson's …, 2023 - nature.com
Dopamine dyshomeostasis has been acknowledged among the determinants of nigrostriatal
neuron degeneration in Parkinson's disease (PD). Several studies in experimental models …

In situ architecture of neuronal α-Synuclein inclusions

VA Trinkaus, I Riera-Tur, A Martínez-Sánchez… - Nature …, 2021 - nature.com
The molecular architecture of α-Synuclein (α-Syn) inclusions, pathognomonic of various
neurodegenerative disorders, remains unclear. α-Syn inclusions were long thought to …

Lipids shape brain function through ion channel and receptor modulations: physiological mechanisms and clinical perspectives

S Incontro, ML Musella, M Sammari… - Physiological …, 2025 - journals.physiology.org
Lipids represent the most abundant molecular type in the brain, with a fat content of∼ 60%
of the dry brain weight in humans. Despite this fact, little attention has been paid to …

VAMP2 regulates phase separation of α-synuclein

A Agarwal, A Chandran, F Raza, IM Ungureanu… - Nature Cell …, 2024 - nature.com
Abstract α-Synuclein (αSYN), a pivotal synaptic protein implicated in synucleinopathies such
as Parkinson's disease and Lewy body dementia, undergoes protein phase separation. We …

The N-terminal acetylation of α-synuclein changes the affinity for lipid membranes but not the structural properties of the bound state

M Runfola, A De Simone, M Vendruscolo… - Scientific Reports, 2020 - nature.com
The aggregation of α-synuclein (αS), a protein abundant at presynaptic terminals, is
associated with a range of highly debilitating neurodegenerative conditions, including …